DU

DuChemBio Co, LTD

Develops & commercializes PET/CT tracers for diagnosing cancer & neurological disorders.

176750 | KO

Overview

Corporate Details

ISIN(s):
KR7176750008
LEI:
Country:
South Korea
Address:
서울특별시 마포구 와우산로 81(서교동, 서봉갤러리), 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

DuChemBio Co., Ltd. is a radiopharmaceutical company specializing in the development, manufacturing, and commercialization of products for nuclear medicine. The company focuses on producing innovative tracers for Positron Emission Tomography (PET/CT) scans, primarily used for the diagnosis and treatment of cancer and neurological disorders like Parkinson's disease. Operating a fully integrated business model, DuChemBio manages the entire value chain from research and development to production in its GMP-compliant facilities and sales. Its mission is to develop novel diagnostic and therapeutic agents and achieve successful commercialization both domestically and globally. The company also imports and distributes related medical equipment.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-01 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.9 KB
2025-08-18 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 7.0 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.4 MB
2025-08-11 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 7.1 KB
2025-06-02 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-05-21 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.7 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.6 MB
2025-05-13 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-03-31 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 23.4 KB
2025-03-31 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 10.3 KB
2025-03-31 00:00
Post-Annual General Meeting Information
상호변경안내
Korean 5.4 KB
2025-03-31 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 14.9 KB
2025-03-21 00:00
Audit Report / Information
감사보고서제출
Korean 25.0 KB
2025-03-21 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 469.0 KB
2025-03-17 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집공고
Korean 962.1 KB

Automate Your Workflow. Get a real-time feed of all DuChemBio Co, LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for DuChemBio Co, LTD

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for DuChemBio Co, LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

GENOLUTION INC. Logo
Develops molecular diagnostic and RNAi solutions for genetic testing and life sciences research.
South Korea
225220
Genome&Company Logo
Clinical-stage biopharma developing cancer therapies using microbiome, immune inhibitors, and ADCs.
South Korea
314130
Develops molecular diagnostics using DNA methylation biomarkers for early cancer detection.
South Korea
228760
Genomtec S.A. Logo
Develops a mobile platform for rapid, precise genetic diagnostics at the point-of-care.
Poland
GMT
GENOTECH CORP. Logo
A biotech firm offering gene synthesis, genome analysis, and biopharmaceutical products globally.
South Korea
066830
Genprex, Inc. Logo
A clinical-stage firm developing non-viral gene therapies for cancer and diabetes.
United States of America
GNPX
Gentian Diagnostics ASA Logo
Develops & manufactures IVD immunoassays for human & veterinary disease diagnostics.
Norway
GENT
GERON CORP Logo
Commercializes an approved, first-in-class telomerase inhibitor for blood cancers.
United States of America
GERN
GH Research PLC Logo
Clinical-stage biopharma developing mebufotenin therapies for psychiatric disorders.
United States of America
GHRS
GI Innovation Inc. Logo
Develops fusion protein biologics for oncology, allergic, and metabolic diseases.
South Korea
358570

Talk to a Data Expert

Have a question? We'll get back to you promptly.